Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers

Antibody–drug conjugates (ADCs) are targeted therapeutics generated by conjugation of cytotoxic small molecules to monoclonal antibodies (mAbs) via chemical linkers. Due to their selective delivery of toxic payloads to antigen-positive cancer cells, ADCs demonstrate wider therapeutic indexes compare...

Descripción completa

Detalles Bibliográficos
Autor principal: Peng, Haiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Mini review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597957/
https://www.ncbi.nlm.nih.gov/pubmed/34805745
http://dx.doi.org/10.1093/abt/tbab023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597957/
https://www.ncbi.nlm.nih.gov/pubmed/34805745
http://dx.doi.org/10.1093/abt/tbab023

Ejemplares similares